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Background: The Butyrophilin-like (BTNL) proteins are likely to play an important role in inflammation and immune
response. Like the B7 protein family, many human and murine BTNL members have been shown to control T
lymphocytes response, and polymorphisms in human BTNL2 have been linked to several inflammatory diseases,
such as pulmonary sarcoidosis, inflammatory bowel disease and neonatal lupus.
Results: In this study we provide a comprehensive population, genomic and transcriptomic analysis of a 56-kb
deletion copy number variant (CNV), located within two segmental duplications of two genes belonging to the
BTNL family, namely BTNL8 and BTNL3. We confirm the presence of a novel BTNL8*3 fusion-protein product, and
show an influence of the deletion variant on the expression level of several genes involved in immune function,
including BTNL9, another member of the same family. Moreover, by genotyping HapMap and human diversity
panel (HGDP) samples, we demonstrate a clear difference in the stratification of the BTNL8_BTNL3-del allele
frequency between major continental human populations.
Conclusion: Despite tremendous progress in the field of structural variation, rather few CNVs have been
functionally characterized so far. Here, we show clear functional consequences of a new deletion CNV
(BTNL8_BTNL3-del) with potentially important implication in the human immune system and in inflammatory and
proliferative disorders. In addition, the marked population differences found of BTNL8_BTNL3-del frequencies
suggest that this deletion CNV might have evolved under positive selection due to environmental conditions in
some populations, with potential phenotypic consequences.Background
The human genome has been shown to be quite plastic,
with many regions presenting gains and losses of genetic
material amongst individuals, also known as copy num-
ber variants (CNVs) [1]. Both germline and somatic
CNVs have been found to play important roles in several
disorders, including neuropsychiatric, infectious and
autoimmune diseases, and cancer [2-5]. In addition, vari-
ation in copy number has been shown to be a major
driving force in evolution, especially within the primate
lineage. Compared to other mammals, such as rat and* Correspondence: xavier.estivill@crg.eu
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reproduction in any medium, provided the ormouse, the genome of humans and great ape species is
characterized by a significant enrichment in CNVs [6]. A
high percentage of these variants (25%-50%) are located
in close proximity to or are part of segmental duplica-
tions (SDs), also called low-copy repeat (LCRs) elements,
which present blocks of highly (>95%) identical sequences
generated during primate evolution [7,8]. Regions
enriched in LCRs predispose to genomic rearrangement
during meiosis, originated by non-allelic homologous re-
combination (NAHR) between repetitive LCR elements
[9]. Interestingly, CNVs that overlap with SDs have been
shown to be especially rich in gene and pseudogene con-
tent, and therefore are likely to be of clinical importance.
Moreover, genes with functions related to immunity and
infection are enriched in CNVs, and most primate-specific
hotspots for CNVs formation have been found inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Aigner et al. BMC Genetics 2013, 14:61 Page 2 of 12
http://www.biomedcentral.com/1471-2156/14/61genes with roles in immune or environmental response,
suggesting an association between CNVs and SDs in
human health [10,11].
The precise structure of many CNVs and their potential
functional consequences are still largely unknown. In the
present study, by using lymphoblastoid cell lines (LCL) de-
rived from human subjects of European ancestry, we
undertook a systematic genetic, gene expression and evolu-
tionary analysis of a previously uncharacterized 56-kb dele-
tion CNV, located on the subtelomeric region of human
chromosome 5q35.3, in a cluster with several genes encod-
ing tripartite motif-containing (TRIM) proteins and genes
involved in the olfactory system. We show that the
breakpoints of the deletion are located within two primate-
specific SDs of two genes belonging to the butyrophilin-
like (BTNL) protein family, and that the polymorphic
deletion (BTNL8_BTNL3-del allele) leads to the formation
of a new fusion gene (BTNL8*3). We confirm the presence
of a novel BTNL8*3 fusion-protein product, and show an
influence of the deletion variant on the expression level of
neighbouring gene BTNL9 and several other genes in-
volved in immune response and cancer, thus suggesting an
involvement of this CNV in specific biological pathways.
Moreover, we have found differences in the frequency of
the deletion allele amongst major continental ethnic
groups, being rare in African and Oceanic populations but
common in Asians, Americans and Europeans. After care-
fully looking for tagging single nucleotide polymorphism
(SNPs) that could be used as a surrogate for the deletion,
we only were able to identify a suitable tag SNP in some
populations tested, suggesting that the CNV is a recent
and recurrent event in humans. Taken together, our find-
ings show functional consequences of a novel deletion
polymorphism with impact in world population’s distribu-
tion and potential implications in physiological processes
of immune response and proliferation.
Results
Array-CGH analysis of chromosome 5q35.3 reveals a
56-kb polymorphic deletion
By using the human Agilent 244 K whole-genome array
and consequent customized Multiplex Ligation-dependent
Probe Amplification (MLPA) analysis of LCLs derived
from HapMap samples, we found a potential CNV, located
on chromosome 5q35.3. We next developed a direct PCR
amplification assay to map the breakpoints of the CNV,
finding that it consists of a ~56-kb deletion polymorphism
(chr5:180375027–180430596 in hg19) recently reported
by Kim et al. [12]. The CNV removes the genomic
sequence between intron four of BTNL8 and intron four
of BTNL3, resulting in a new BTNL8*3 fusion gene with-
out any alterations in the coding sequence (Figure 1A).
The breakpoints of the deleted allele are located in
two ~1.6-kb SD that share 98% identity and are separatedby ~55,570 nucleotides on the BTNL8 and BTNL3 genes,
indicating that the deletion resulted from a NAHR event.
Each 1.6-kb SD contains parts of intron four to exon eight
of BTNL8 and BTNL3. The crossover occurred some-
where within 112-bp of identical sequence of these two
genes in intron four (Figure 1B).
Linkage disequilibrium with SNPs in the genomic region
To evaluate linkage disequilibrium (LD) between
BTNL8_BTNL3-del and tag single nucleotide polymor-
phisms (SNPs) covering the BTNL8 and BTNL3, sur-
rounding haplotype structure, we genotyped the 56-kb
deletion in 1,103 unrelated individuals included in the
HapMap Phase III project and searched for potential tag-
ging SNPs, based on the genotypes on the HapMap data
release 28 (http://hapmap.ncbi.nlm.nih.gov), and an inde-
pendent control cohort of 2,000 Spanish unrelated individ-
uals. Several SNPs were in high LD (r2 > 0.9) with the
deletion in the CEU, CHD, CHB, MEX, GHI and JPT sets.
The best taggers in these populations were rs2387715 and
rs4700772 (CEU, CHB, JPT, r2 = 1; MEX, r2 = 0.95; CHD,
r2 = 0.96; and GHI, r2 = 0.94). Finally, in the Tuscan
population only one SNP was selected as a tagger,
rs10063135 (TSI, r2 = 0.81). In contrast, we could not
identify a proxy SNP (r2 > 0.8) in African-ancestry popula-
tions (ASW, LWK, MKK or YRI). In fact, the SNPs in
higher LD in these populations were: rs3733755 (YRI, r2 =
0.38); rs2387715 (ASW, r2 = 0.69; MKK, r2 = 0.32); and
rs4701016 (LWK, r2 = 0.36) (Table 1). Based on these LD
results, we selected three of these SNPs (rs3733755,
rs10063135 and rs4700772) for genotyping 2,000
Spanish samples, and none of them showed strong LD
(r2 > 0.8) with the deletion in our dataset: rs10063135,
r2 = 0.63; rs3733755, r2 = 0.63, and rs4700772 r2 = 0.724.
Population differences in the frequency of the
BTNL8_BTNL3-del allele
To check whether population-based differences exist for the
BTNL8_BTNL3-del allele, HapMap samples from 120 CEU;
90 CHB; 90 JPT; 120 YRI; 43 ASW; 100 CHD; 100 GIH; 100
LWK; 90 MEX; 150 MKK; 100 TSI; and 2,000 Spanish sam-
ples were genotyped. In addition, we analyzed 1,007 samples
from 39 ethnical groups of the Centre d’Etude du Poly-
morphisme Humain (CEPH) Human Genome Diversity
Panel (HGDP) (Additional file 1: Table S1 and Table S2).
We observed clear differences in allele frequencies be-
tween major continental groups. The deletion is signifi-
cantly underrepresented in Oceanic, central Asian and
Sub-Saharan African populations but significantly over-
represented in European and American populations. In
CEU population, 12% are homozygous for the deletion al-
lele and 41% carry at least one BTNL8_BTNL3-del allele,
corresponding to an allele frequency of 34%. In the CHB-
JPT population the deleted allele shows a frequency of
Figure 1 Region of the BTNL gene cluster containing the BTNL8_BTNL3-del allele and sequence structure of deletion. (A) The figure
shows 200-kb of the genomic region on human chromosome 5. The expected transcripts of the three genes in this region are shown with their
transcript orientation. The CNV region, which is indicated by the dashed line, removes 56-kb, from intron four of BTNL8 to intron four of BTNL3.
The black-yellow dashed box represents the SD shared between BTNL8 and BTNL3. PCR assays were designed to distinguish between non-deleted
and deleted alleles (short arrows show position of PCR oligonucleotides). The PCR assay amplifies a ~420-bp product for the non-deleted allele,
and a ~340-bp fragment for the deleted allele (bottom). Results from the PCR assay are shown for seven LCLs. (B) The deleted allele shows long
homologous stretches at its breakpoints (~1.6-kb sequence blocks of 98% identity, of which 300-bp are shown aligned here) and thus probably results
from non-allelic homologous recombination (NAHR). The “cross-over” occurred somewhere within 112-bp of identical sequence indicated
as “NAHR-region”.
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significantly reduced frequency for the BTNL8_BTNL3-del
allele of 9% and 3%, respectively (Figure 2, Additional file
1: Table S3). In order to rule out large-scale genotyping er-
rors, we calculated estimates of Hardy-Weinberg equilib-
rium for each of the 39 HGDP populations, as well as for
all continental HapMap and HGDP groups, but could not
observe any significant deviations except for Hezhen
(China), Cambodian and Orcadian population, which
most likely is due to the small sample size (10, 10 and 15
individuals, respectively) sequenced (Additional file 1:
Table S3 and Table S4).
The BTNL8*3 56-kb deletion leads to a new chimeric
transcript and protein product
To further analyse the CNV at the transcriptional level,
LCLs were genotyped and RT-PCR analysis and subsequent
sequencing was carried out on samples containing none,
one or two copies of the BTNL8_BTNL3-del allele. In celllines heterozygous and homozygous for the deletion
CNV we detected a new, in-frame, fusion transcript,
BTNL8*3, which consisted of the juxtaposition of
exons one to four of BTNL8 to exons five to eight of
BTNL3 (Figure 3A). Thus, the predicted BTNL8*3 tran-
script would contain the 3′-UTR from BTNL3, but the
BTNL8 upstream regulatory signals. In a next step, allele-
specific quantitative RT-PCR (qPCR) analysis was
performed on LCL and tissue samples heterozygous for
the BTNL8_BTNL3-del allele. A chimeric BTNL8*3 tran-
script could be identified in all samples (Figure 3B). How-
ever, the fusion transcript was present at a significantly
reduced level, compared to BTNL8 mRNA with which it
shares its complete upstream regulatory region. Moreover,
western-blot analysis revealed the presence of a novel
BTNL8*3 fusion protein in LCLs carrying the deleted al-
lele, indicating the presence of a novel protein (Figure 3C).
BTNL8 and BTNL3 share 68.5% similarity in their protein
sequences (Additional file 1: Figure S1). The resulting
Table 1 List of SNPs tested for LD with the BTNL8*3 deletion CNV
ASW CEU CHB CHD GHI JPT LWK MKK MEX TSI YRI
rs Number Position Distance to
deletion
breakpoints
D' r2 D' r2 D' r2 D' r2 D' r2 D' r2 D' r2 D' r2 D' r2 D' r2 D' r2
rs1904435 180322735 52,292 0.94 0.834 1 0.77 0.81 0.596 1 0.829 0.31 0.03 0.93 0.537 0.8 0.495 0.69 0.099
rs7735361 180329359 45,668 1 0.086 0.91 0.843 1 0.658 1 0.706 0.94 0.663 1 0.796 0.3 0.034 0.37 0 0.82 0.58 0.8 0.54 0.03 0
rs17704291 180336849 38,178 0.8 0.43 1 0.96 0.94 0.889 - - - - 1 1 0.28 0.04 0.94 0.76 0.9 0.68 0.3 0.06
rs4700772 180341845 33,182 0.8 0.539 1 1 1 1 1 0.966 1 0.946 1 1 0.8 0.25 0.63 0.322 1 0.952 1 0.752 0.8 0.3
rs2387715 180361266 13,761 0.8 0.694 1 1 1 1 1 0.966 1 0.944 1 1 0.8 0.237 0.63 0.322 1 0.952 1 0.749 0.8 0.33
rs3733755 180374484 543 1 0.686 1 0.815 1 0.692 1 0.451 1 0.588 1 0.486 1 0.31 0.77 0.195 1 0.86 1 0.598 1 0.38
deletion 180375027-
180430596
rs10063135 180432024 1,428 1 0.177 1 0.923 1 0.946 1 0.966 1 0.545 1 0.754 0.4 0.161 0.8 0.101 1 0.82 0.97 0.81 0.8 0.09
rs4700774 180434216 3,620 1 0.473 1 1 1 0.945 1 0.966 1 0.893 1 1 0.84 0.12 0.5 0.09 0.95 0.903 1 0.752 0.2 0.07
rs7721042 180439488 8,892 1 0.958 1 0.939 - - - - 1 1 - - - - 0.03 0
rs11249756 180455372 24,776 1 0.473 1 0.923 1 0.945 0.96 0.86 0.8 0.64 1 1 0.4 0.161 0.44 0.07 0.94 0.807 0.94 0.72 0.2 0.07
rs4701016 180458539 27,943 1 0.686 0.91 0.733 1 0.646 0.86 0.37 0.6 0.3 1 0.486 1 0.364 0.2 0.01 0.85 0.719 0.9 0.55 1 0.3
rs6868418 180458813 28,217 1 0.686 0.91 0.733 1 0.646 0.86 0.4 0.6 0.3 1 0.486 1 0.364 - - - - - - 1 0.3
HapMap phase III populations were screened for tagging SNPs for the BTNL8_BTNL3-del allele. Several SNPs could be identified in Eastern Asian (CHB, CHD and JPT), American (GIH and MEX) and CEU population.
However, no LD could be observed in African population (ASW, LKW, MKK and YRI) and only a weak association for rs10063135 could be detected in TSI population.
r2 higher than0.8 indicates a significant correlation. ASW, individuals with African ancestry from Southwest USA; CEU, individuals from Utah with northern and western European ancestry; CHB, Han Chinese from
Bejing; CHD, Han Chinese from Denver, Colorado; GIH, Gujarati Indians from Houston, Texas; JPT, Japanese from Tokyo; LWK, Luhya from Webuya, Kenya; MEK, individuals with Mexican ancestry from Los Angeles,



















Figure 2 World-wide distribution of the BTNL8_BTNL3-del allele in different human populations. Genotype analysis of populations is
shown over a map of the world. The deletion frequency is indicated by the black part of the pie in the chart. Total number of individuals
genotyped is given in red.
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and Ig-like V domain, and the transmembrane domain of
BTNL8 and the intracellular B30.2 domain at its C-
terminus (Figure 3D).
BTNL8*3 CNV affects expression of neighboring
gene BTNL9
BTNL8 and BTNL3 form a cluster together with another
gene of the same family, BTNL9. Both, the BTNL9 geneFigure 3 Identification of a chimeric BTNL8*3 product. (A) In LCLs carr
mRNA product could be detected by RT-PCR. (B) Allelic expression differen
BTNL8*3 allele, the non-deleted BTNL8 allele was expressed threefold highe
western blot analysis revealed a novel protein in LCL cells expressing the d
expression. (D) The putative protein resulting from the BTNL8*3 deletion C
the TM domain of BTNL8 and the cytoplasmic B30.2 domain of BTNL3.and its promoter region are intact in the BTNL8_BTNL3-
del allele, thus BTNL9 expression would not be expected
to be affected by the BTNL8*3 deletion CNV. However, it
is known that genomic neighborhoods may influence the
expression level of a gene by a positional effect. This can
be achieved by affecting cis-regulatory elements, such as
transcription factor binding sites, or by re-organization of
chromosomes into territories within the nucleus [13,14].
To test whether this is the case for BTNL9 and otherying one or two copies of the BTNL8_BTNL3-del allele, a fusion BTNL8*3
ces are shown in individual tissues. In tissues heterozygous for the
r than the BTNL8*3 allele (all tissues combined). (C) Representative
eleted allele. The band intensities were normalized to tubulin
NV would contain the extracellular IgV-like and IgC-like domains and
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BTNL9,TRIM7 and TRIM41 mRNA expression level in 30
LCLs (10 of each genotype) by qPCR analysis. Expression
of BTNL9 could be detected at a moderate level in all cell-
lines homozygous for the wild-type allele. In contrast,
cell-lines heterozygous for the deletion expressed
BTNL9 at a significantly decreased amount, and in
cell-lines homozygous for the deletion BTNL9 expres-
sion was almost not detectable (Figure 4A). In line,
western-blot analysis revealed a strong decrease in pro-
tein expression levels in cell lines heterozygous or homo-
zygous for the BTNL8_BTNL3-del allele (Figure 4B). In
addition, a slight but not significant effect could be
observed at the expression-level of TRIM7, which is lo-
cated ~200-kb from the deletion (data not shown), imply-
ing that indeed it is due to a positional effect, although
other possibilities cannot be ruled out yet.
The BTNL8*3 deletion CNV affects expression of several
genes involved in immune response, cancer and
developmental disorders
Next we looked at potential downstream targets by
utilizing transcriptional data from the Illumina genome-
wide expression arrays of LCLs from 56 unrelatedFigure 4 Effect of BTNL8-BTNL3_del on BTNL9 level in LCLs.
BTNL9 mRNA and protein levels were measured by RT-qPCR
and western-blot analysis, respectively. (A) For each genotype
expression-level of five different samples were measured. Samples
containing at least one deleted allele show significant reduced
amount in BTNL9 mRNA level. (B) Representative western-blot shows
expression of BTNL9 in cell homozygous for the deletion versus cells
homozygous for the non-deleted allele. The band intensities were
normalized to tubulin expression.individuals, derived from CEU population [15]. Of the
56 cell-lines tested, 25 were homozygous for the inser-
tion allele, 18 were heterozygous and 13 were homozy-
gous for the deletion allele. In total, we found 20
genes showing a significant (p < 0.05) differential ex-
pression according to the BTNL8/BTNL3 genotype
(data not shown). Unfortunately, none of the genes
deregulated by the CNV identified earlier, BTNL9 and
TRIM7, were expressed at a detectable level. To verify
the microarray data, we performed qPCR analysis on
10 LCLs homozygous for the wild-type allele and 10
LCLs homozygous for the deletion allele and tested all 20
genes found deregulated at the microarray. Of the 20
genes, nine could be validated as differentially expressed
in LCLs homozygous for the BTNL8_BTNL3-del allele
(Figure 5A).
In a next step, we submitted the data to Ingenuity
Pathway Analysis (IPA) for functional classification and
to check whether these genes interact with each other in
regulatory networks and biological pathways. In addition
we included the genes directly affected by the CNV;
BTNL8, BTNL3 and BTNL9. The top functions mapped
by IPA out of the 13 genes were: Hematopoiesis (3 genes,
p < 4.27E-05), Immune Cell Trafficking (4 genes, p < 4.27-
05), Hematological System Development and Function (5
genes, p < 7.93E-05), Tissue Morphology (7 genes, p <
2.40E-04) Connective Tissue Development and Function
(3 genes, p < 3.08E-04). In addition, IPA formed one
well-defined network, with function in cell morphology,
cellular development and embryonic development, with
nine mapped genes involved (Figure 5B). It should be
noted that so far little is known about the function and
operation mechanism of BTNL8, BTNL3 and BTNL9.
Therefore they are not sufficiently well annotated for
pathway analysis by Ingenuity Pathway.
Discussion
CNVs are thought to significantly contribute to population-
based adaptive evolution due to variability in expression
levels. [16]. Especially recently emerged genes may
have significantly contributed to evolutionary change
and phenotypic adaptation in more recently diverged
evolutionary lineages [17]. However, despite intensive
work in the field, most CNVs and new resulting genes
are so far, overall, rather poorly characterized at the
functional level.
In this study, we provide a detailed functional ana-
lysis of a novel 56-kb deletion CNV involving two
primate-specific genes of the BTNL family, namely
BTNL8 and BTNL3, who share 80% homology in their
coding sequence. The CNV has arisen in two 1.6-kb
SD blocks of 98% identity, suggesting that the deletion
occurred due to a NAHR event. CNVs arisen from
NAHR tend to recur due to the unstable nature of the
Figure 5 Differential expression of genes depending on BTNL8/BTNL3 genotype. (A) Nine genes could be confirmed by RT-qPCR analysis
to be differentially expressed in LCLs homozygous for the BTNL8_BTNL3-del allele. Red, increased mRNA level; green, decreased mRNA level in
LCLs homozygous for the CNV. (B) Network of genes formed by Ingenuity Pathway Analysis. Genes depicted in red (increased mRNA level) and
green (decreased mRNA level) were confirmed by RT-qPCR analysis to be differentially expressed in LCLs homozygous for the CNV. Genes
depicted in white were not found to be deregulated even though they are part of the same network.
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ferent haplotypes that share common endpoints.
Multiple genomic disorders as Williams-Beuren syn-
drome, Charcot-Marie Tooth disease, schizophrenia,
and developmental delay have been assigned to NAHRevents between misaligned LCRs [18-21], making
NAHR the most common mechanism mediating recur-
rent microdeletions and microduplications.
By carefully looking at SNPs data of the International
HapMap project and through our own genotyping data,
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LD (r2 > 0.8) with the BTNL8*3 CNV in Eastern Asian,
American and northern European populations. In con-
trast, no LD could be detected in African, Italian and
Spanish populations. Especially African populations have
been shown to be highly heterogeneous and to signifi-
cantly vary in their haplotype structure and LD from
other populations [22]. However, also southern European
subgroups as Italian, Spanish and Greek, have been shown
to differ in their haplotype composition from northern
and western European populations [23]. This most likely
results from large and constant migratory influences and
admixture with other European and North African popu-
lations. These substantial differences between northern
and southern European subgroups imply that many varia-
tions found through genome-wide association studies
(GWAS) studies carried out on northern and western
European population may not be replicated in southern
European subgroups. Moreover, the absence of a tagging
SNP in some populations has important implications for
the interpretation of association studies. It stresses that
unless a direct genotyping assay is applied for the
BTNL8*3 CNV, its potential phenotypic impact may be
overlooked in GWAS.
The BTNL8_BTNL3-del allele has been found at higher
frequencies in European, East Asian and American pop-
ulations, as compared to African, Oceanic and Middle
Eastern populations. Ethnicity plays an important role
in inter-individual variability of the immune system.
Through recurrent exposure to different pathogens, eth-
nic groups have selected genetic adaptations that provide
resistance or reduced susceptibility to infection [24]
meaning that many times CNVs result in an advanta-
geous phenotype for some populations [25,26]. An ex-
ample of a reduction in copy number being beneficial
has been suggested for the α-globin locus, where it
increases resistance to malaria infection and susceptibil-
ity to mild α-thalassemia. In regions where malaria is
endemic, the deleted form of the α-globin gene can be
found at an unusually high degree [27,28]. Other exam-
ples where the number of gene copies positively corre-
lates with infection are FCGR3B and DEFB4 genes,
which are associated with glomerulonephritis, and
Crohn’s disease, respectively [29,30]
Here we show that, in accordance with the partial de-
letion of these genes, the BTNL8 and BTNL3 proteins
were not expressed in LCLs homozygous for the dele-
tion, and they were found at a significantly reduced
amount in LCLs carrying one deleted allele. RT-PCR
analysis, sequencing and western blot analysis revealed a
new BTNL8*3 fusion product without any alterations in
the coding frame, suggesting the existence of a novel,
functional protein. In addition, BTNL9, another member
of the butyrophilin family, was down-regulated in LCLscarrying the BTNL8_BTNL3-del allele. However, the
function of BTNL8, BTNL3 and BTNL9 is yet unknown;
therefore, here we can only speculate what might be the
consequence of the deletion.
The BTNL proteins belong to the butyrophilin (BTN)
family. The eponymous BTN protein (BTN1A1) is a type
I transmembrane glycoprotein whose expression is re-
stricted to the mammary gland during lactation, where it
is involved in the secretion of milk fat globules [31]. All
BTN family members contain a signal peptide at their
N-terminus, two Ig-like-domains (IgV and IgC) and
a transmembrane-domain. The extracellular domain
shows structural similarities to those of the B7 family, a
protein family of co-stimulatory molecules involved in T
cell activation [32]. In contrast to B7 proteins, most
BTN members harbour a cytoplasmic B30.2 domain at
their C-terminus. Like the B7 protein family, several hu-
man and murine BTN and BTNL family members have
been shown to control T cell response [33]. While the
B7 family of ligands and their receptors can regulate T
cell response either through their positive (e.g. B7-1, B7-
2, ICOS) or negative (e.g. PD-L1, PD-L2, B7-H3, B7-H4)
co-stimulatory molecules, BTNs so far only have been
found to act through co-inhibition [34-37]. In addition,
polymorphisms in the human gene encoding for BTNL2
have been linked to a growing number of inflammatory
diseases, e.g. sarcoidosis, myositis and inflammatory
bowel disease [38-40]. Moreover, human BTN2A1 has
been shown to modulate immature dendritic cells (DC)
by binding to Dendritic Cell-Specific Intercellular adhe-
sion molecule-3-Grabbing Non-integrin (DC-SIGN)
[41], and Btnl1 has been recently found to regulate in-
teractions with intraepithelial γδT lymphocytes in the
murine small intestine by suppressing pro-inflammatory
mediators of the NFκB pathway, such as IL-6, IL-15,
CXCL1, and CCL4 [42]. In addition, many members of
the B7-homolog (B7-H) family, such as PD-1 and
CTLA-4, are expressed on tumour cells in various can-
cers, where they can be exploited by the cancerous cells
to escape from immune destruction and impede B7
ongoing immune processes [43,44]. The presence of the
deletion and the subsequent absence or reduced expression
of the encoded proteins would allow a stronger response
against tumour cells, implying that the BTNL8_BTNL3-del
allele could act as a positive modulator of anti-tumour im-
munity. However, co-inhibitory molecules such as CTLA-4,
PD-1 and BTLA have been shown to be crucial for the pre-
vention of autoimmunity and polymorphism or deficiency
of these molecules are associated with genetic susceptibility
to autoimmune diseases in human and mice [45]. Follow-
up studies on the BTNL proteins will shed more light on
their function in autoimmune diseases and cancer.
BTNL8 and BTNL3 are primate-specific genes, while
BTNL9 has a clear ortholog in mice. Human BTNL8 and
Aigner et al. BMC Genetics 2013, 14:61 Page 9 of 12
http://www.biomedcentral.com/1471-2156/14/61BTNL3 expression is primarily restricted to tissues of the
digestive tract and at a lower level to spleen, thymus and
lung. In addition BTNL3 is expressed in neutrophils and
BTNL8 in eosinophils and at a reduced amount in neu-
trophils. In contrast, BTNL9 is mainly expressed in B
cells and lymphoid organs, e.g. thymus, spleen, bone
marrow and lymph nodes [46,47]. Due to the high se-
quence homology and the similar expression-profile of
BTNL8 and BTNL3 it is possible that the new BTNL8*3
fusion-protein compensates for the BTNL8 and BTNL3
wild-type proteins. However, more information is needed
about the functions of BTNL8, BTNL3 and BTNL8*3
and the pathways they are involved in. Since almost all
members of the BTN and BTNL families are highly
expressed in the intestine [46], it has been postulated
that these proteins act through a combined immunosup-
pressive effect, rather than a big impact of individual
molecules [48]. Therefore, it would be interesting to
check for the consequences of the CNV in diseases asso-
ciated with polymorphisms in BTN and BNTL genes,
e.g. BTNL2 in Crohn’s disease or ulcerative colitis. Never-
theless, a review of the published GWAS data in these
two disorders did not reveal an association with the po-
tential tagging SNPs for the deleted allele (rs2387715,
rs4700772 or rs10063135), although these SNPs are
present in the affy 6.0 (rs2387715) and Illumina Omni 1
and human 1 M arrays (rs4700772 and rs10063135. There
is, nevertheless, a replicated association on Chron’s disease
to the 5q35 region around CPEB4 gene [49,50], about
3 Mb away from the deletion.
Interestingly, when investigating gene expression changes
with regard to the BTNL8_BTNL3-del allele, we found
TNF and the ERK1/AKT pathway to be central hubs of
the network influenced by the deletion CNV in LCLs.
TNF, ERK1 and AKT are important players in signal trans-
duction pathways and key components of the immune re-
sponse in humans and even a slight deregulation of those
proteins might have an important impact in the response
to pathogens. However, even though the HapMap reposi-
tory represents a fantastic source for genetic studies, the
analysis was limited due to the use of LCLs, which might
not be the main cell-type where the BTNL8*3 CNV affects
expression levels, since BTNL3 and BTNL8 are predomin-
antly expressed in the digestive tract. Follow-up studies
using other cell types will be needed.
Conclusion
In summary, we provide a broad, functional analysis of a
common deletion variant at several levels. We demon-
strate the existence of a new fusion-protein, implying
functional consequences of the CNV. Moreover, we
proof structural changes at the immediate neighborhood
of the CNV likely due to a position effect, as well as
overall changes in the general expression-level of severalgenes involved in immune regulation and proliferation.
Although the exact molecular function of BTNL8,
BTNL3 and BTNL9 remains unknown, the high fre-
quency of the deletion in some populations, its struc-
tural homology to B7 proteins and its tissue distribution
make the CNV a potentially interesting candidate for
diseases associated with infection and inflammation,
especially in the gut.
Methods
Samples
1,103 samples from the International HapMap Phase III
project, 1,007 individuals from the CEPH-HDGP cohort,
and 2,000 Spanish samples were genotyped [51,52].
The samples consisted of 120 individuals from Utah with
northern and western European ancestry (CEU); 90
Han Chinese from Bejing (CHB); 90 Japanese from
Tokyo (JPT); 120 Yoruba form Ibadan, Nigeria (YRI); 43
individuals with African ancestry from Southwest USA
(ASW); 100 Han Chinese from Denver, Colorado (CHD);
100 Gujarati Indians from Houston, Texas (GIH); 100
Luhya from Webuya, Kenya (LWK); 90 of Mexican an-
cestry from Los Angeles, California (MEX); 150 Maasai
from Kinyawa, Kenya (MKK); 100 Toscans from Italy
(TSI); and an independent control cohort of 2,000
Spanish unrelated individuals. The analysis from the
CEPH-HGDP includes individuals from 51 different
populations and excludes samples previously identified
as duplicates as well as the genotypically abnormal sam-
ples 770 and 980 [53]. Individual genotypes are pro-
vided in Additional file 1: Table S1 and Table S2.
Genotyping and sequence analysis
To identify possible CNVs, we used the Human Genome
CGH Microarray Kit (Agilent 244 k aCGH microarray
kit) with covers the genome with a 10-kb resolution be-
tween probes. aCGH was performed according to manu-
facturer’s protocol and as described previously [54].
Results obtained for the 5q35.3 region were confirmed
by MLPA analysis and long range PCR analysis. Se-
quences of MLPA probes used in the study are listed in
Additional file 1: Table S5.
Statistical analysis
Linkage disequilibrium was calculated and visualized with
Haploview. Statistical differences of allelic distributions
among populations were assessed performing a chi-square
test.
PCR genotyping assay
Two allele-specific PCR assays using fluorescent oligo-
nucleotides, were designed to distinguish non-deletion
and deletion alleles based on primer sequences: non-del
forward: 5′-(HEX)GGCACAACCCAGAACAAAGT-3′,




GGT-3′. DNA from HapMap and CEPH-HGDP samples
was available in the lab. Quality of DNA was checked on
a 1% agarose gel prior PCR and samples with degraded
DNA were excluded from the analysis. PCR was carried
out in a GeneAmp PCR System (Applied Biosystems)
using 100 ng of genomic DNA/reaction. Conditions con-
sist of an initial denaturation step of 1 min at 95°C,
32 cycles of 30 s at 95°C denaturation, 30 s annealing at
62.5°C and 25 s elongation at 72°C and a final extension
step at 72°C for 25 min. Non-deletion primers were lo-
cated inside the deleted sequence and generated a 420-
bp PCR product. Deletion primers amplified across the
deletion breakpoints and resulted in a 340-bp product.
Real-Time PCR analysis
Total mRNA was extracted from cells using the miRNA
easy Kit (Qiagen), samples were treated with DNase I
(Qiagen) for 15 min and 1 to 2 μg of RNA was reverse tran-
scribed using the Superscript VILO kit (Invitrogen)
according to the manufacturer’s protocol. Real time PCR
was carried out using the Light cycler 480 from Roche. The
PCR reaction contained 35 ng of cDNA, 10 pmol of each
of the specific primers and 5 μl SYBR Green master
mix in a final reaction volume of 10 μl. All reactions
were performed in triplicates. Thermal-cycling conditions
consisted of an initial denaturation of 10 min at 98°C, 40 cy-
cles of 15 s at 95°C denaturation, 15 s annealing, and 18 s
elongation at 72°C, and final extension at 72°C for 10 min.
The optimal annealing temperature was determined for
each oligonucleotide-pair individually. Cumulative fluores-
cence was measured after each of the 40 cycles. Product
specific amplification was confirmed by melting curve ana-
lysis. Oligonucleotide sequences used for quantification are
listed in Additional file 1: Table S6. Relative quantification
of gene expression was determined by the construction of a
relative expression calibration curve using serial dilutions of
ACTB and GAPDH as a positive control.
Allele-specific expression profiling
RNA extraction, DNase treatment, first-strand cDNA
synthesis and qPCR were done as described above with
BTNL8 5′-TTTGGCATTGTTGGACTGAA-3′ as for-
ward primer and BTNL3 5′-ACACTCCCACATACCA
CCCT-3′ and BTNL8 5′-TCCTTCCTCCTGTCCACA
TC-3′ reverse primers.
Western blot
Cell lysates were prepared as previously described [55].
Briefly, equal amounts of proteins (300–350 μg) were re-
solved by NuPAGE (4-12%; Invitrogen) and transferred
to nitrocellulose membranes. Proteins were then blockedby incubation in 10% dry milk in TBST (0.1% Tween-20
in TBS) and probed with the indicated Antibody. Blots
were then developed by enhanced chemiluminescence
(ECL; Amersham).
Antibodies
A polyclonal BTNL3 antibody was generated to peptides
YIQHAMYDEEKGTPI, PPSTPPTRVGVFLDYE and YW
VLRLTTEHLYFTF, corresponding to the cytoplasmic re-
gion of human BTNL3, according to standard procedures.
Briefly, the three synthetic peptides were independently
keyhole limpet hemocyanin (KLH)-conjugated, pooled,
and injected into two female New Zealand White rabbits
for antisera production. Pre-immune serum was collected
before immunization and was used as a negative control.
Antisera collected from the immunized rabbits were veri-
fied for reactivity by ELISA against the original peptides
and the human BTNL3 protein. Rabbit BTNL9 antibody
was purchased from Abcam (ab87049). Mouse Tubulin
antibody was purchased from Santa Cruz (sc-5286).
Expression analysis and Ingenuity Pathway Analysis software
Microarray expression data were obtained from Stranger
et al., [15] and analyzed for differences in the expression
level regarding the BTNL8/BTNL3 genotype. The list of
genes found to be influenced by the BTNL8*3 deletion
CNV was submitted to Ingenuity Pathway Analysis (IPA;
Ingenuity® Systems, Redwood City, CA, http://www.in-
genuity.com) to identify common biological pathways. In
addition, gene expression values were included in the input
to identify up and down regulated genes in the pathways.
Additional file
Additional file 1: Figure S1. Protein alignment of BTNL8 and BTNL3.
BTNL8 and BTNL3 share 68.5% similarity in their amino-acid sequences.
Segmental duplication, where cross-over occurred, is highlighted in
yellow. Table S1. Individual genotyping HapMap. Table S2. Individual
genotyping CEPH-HGDP. Table S3. Frequency of deletion by continental
groups. Table S4. CEPH-HGDP genotype frequencies by geographic
location. Table S5. Sequences of MLPA probes. Table S6. Sequences of
oligonucleotides.
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